BioWorld - Friday, December 26, 2025 To read the full story, subscribe or sign in. Endocrine/metabolic Chinese researchers patent new URAT1 inhibitors Dec. 2, 2025 Apichope Pharmaceutical Co. Ltd., Guangzhou Lianrui Pharmaceutical Co. Ltd. and Guangzhou Runlin Pharmaceutical Technology Co. Ltd. have disclosed solute carrier family 22 member 12 (SLC22A12; URAT1) inhibitors reported to be useful for the treatment of hyperuricemia, nephropathy and gout. BioWorld ScienceEndocrine/metabolicPatents